Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.2680
+0.0007 (+0.26%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
February 09, 2022
From
Cybin Inc.
Via
Business Wire
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
February 08, 2022
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62
Via
Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
February 07, 2022
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23
Via
Benzinga
Cybin's Vision Strengthens Position In Emerging Wellness Trend
January 28, 2022
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health...
Via
Benzinga
Cybin Schedules Release of Q3 Results, Conference Call
January 27, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Cybin Marks 2021 Accomplishments, Eyes 'Transformative' 2022
February 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Marks 2021 Accomplishments, Eyes ‘Transformative’ 2022
February 07, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
February 07, 2022
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE.
Via
Benzinga
Psychedelic Stocks Finally In An Upswing
February 06, 2022
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index went up +5.3% last week.
Via
Talk Markets
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
February 04, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
February 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today
February 03, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19
Via
Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
February 02, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17
Via
Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
February 01, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 15.70% at $0.69
Via
Benzinga
Cybin's IRB-Approved Study Begins Enrollment This Year
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Upcoming study supports CYBN’s mission to develop psychedelics...
Via
Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Begins Enrollment This Year
February 01, 2022
Via
Investor Brand Network
Magic Mushrooms For Depression: Clinical Trial Of Active Compound Approved For Patients Using Antidepressants
January 31, 2022
Health Canada has allowed a phase 2 clinical trial of psilocybin in patients currently undergoing treatment with traditional antidepressants.
Via
Benzinga
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
January 31, 2022
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 7.89% at $5.33
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year
January 31, 2022
Via
Investor Brand Network
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 17.86% at $0.57
Via
Benzinga
Cybin’s (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Position in Emerging Wellness Trend
January 28, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
January 27, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Schedules Release of Q3 Results, Conference Call
January 27, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call
January 27, 2022
Via
Investor Brand Network
Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
GAINERS: Mind Medicine (NASDAQ:
Via
Benzinga
< Previous
1
2
...
31
32
33
34
35
36
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.